Abstract A30: Cost‐effectiveness analysis of HER2 testing methods in adjuvant treatment of HER2 breast cancer

2010 ◽  
Author(s):  
Mahima Ashok ◽  
Paul Griffin ◽  
Michael Halpern
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Testing Methods ◽  
Her2 Testing ◽  
Her2 Breast Cancer ◽  
Effectiveness Analysis

scholarly journals Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study)

2005 ◽  
Vol 16 (6) ◽  
pp. 915-922 ◽  
Author(s):  
J. Bonneterre ◽  
C. Bercez ◽  
M.-E. Bonneterre ◽  
X. Lenne ◽  
B. Dervaux
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

Therapie des Mammakarzinoms – Ist die zusätzliche Gabe von Pertuzumab kosteneffektiv?

2020 ◽  
Vol 25 (01) ◽  
pp. 6-6
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Effectiveness Analysis ◽  
Positive Breast Cancer

Garrison L et al. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value Health 2019: 22(4): 408–415 Bis zu 20 % der Frauen, die von Brustkrebs betroffenen sind, zeigen eine erhöhte Konzentration des Humanen Epidermalen Wachstumsfaktor-Rezeptors 2 (HER2). HER2-positiver Brustkrebs führt im Verlauf häufig zu Rezidiven und bedarf einer zielgerichteten Therapie. Garrison et al. untersuchten in diesem Zusammenhang die Kosten-Effektivität einer zusätzlichen Gabe von Pertuzumab.

Sign in / Sign up

Export Citation Format

Share Document